ClinicalTrials.Veeva

Menu

Obesity, Iron Regulation and Colorectal Cancer Risk

University of Illinois logo

University of Illinois

Status

Completed

Conditions

Colon Inflammation
Obesity
Diet Modification
Iron Malabsorption

Treatments

Other: High heme iron diet
Other: Low iron diet
Other: Plant-based high non-heme iron diet

Study type

Interventional

Funder types

Other

Identifiers

NCT03548948
2014-0721

Details and patient eligibility

About

Obesity is an independent risk factor for colorectal cancer (CRC) although the underlying mechanisms have not been elucidated. Dietary nutrients play a key role in both the prevention and promotion of CRC. While iron is an essential nutrient, excess iron is associated with carcinogenesis. Unlike the systemic compartment, the intestinal lumen lacks an efficient system to regulate iron. In conditions when dietary iron malabsorption and intestinal inflammation co-exist, greater luminal iron is associated with increased intestinal inflammation and a shift in the gut microbiota to more pro-inflammatory strains. However, treatments designed to reduce luminal, including diet restriction and chelation, are associated with lower intestinal inflammation and the colonization of protective gut microbes. Obesity is associated with inflammation-induced, hepcidin-mediated, iron metabolism dysfunction characterized by iron deficiency and dietary iron malabsorption. Obesity is also linked to intestinal inflammation. Currently, there is a fundamental gap in understanding how altered iron metabolism impacts CRC risk in obesity.

The investigator's objective is to conduct a crossover controlled feeding trial of: 1) a "Typical American" diet with "high" heme/non-heme iron", 2) a "Typical American" diet with "low" iron, and 3) a Mediterranean diet with "high" non heme iron and examine effects on colonic and systemic inflammation and the gut microbiome.

Enrollment

17 patients

Sex

Female

Ages

55 to 70 years old

Volunteers

Accepts Healthy Volunteers

Inclusion criteria

  • Self-identify as Hispanic, African American, or Caucasian.
  • Meet body mass index (BMI > = 30.0 kg/m2) and C-reactive protein (CRP) criteria (> 2.0 mg/dl)
  • Post-menopausal (no menstruation in the past 12 months)
  • Weight stable (< 3% weight change in the past 3 months)
  • Non-smoker
  • No major medical problems
  • Have a working phone
  • No known allergies, intolerance, medical, secular or religious dietary restrictions

Exclusion criteria

  • Chronic constipation (less than three stools per week for several months)
  • History or intestinal cancer, inflammatory bowel disease, celiac disease, or malabsorptive bariatric surgery
  • Previous intestinal surgery
  • H pylori infection or taking H2 blockers (e.g., Zantac, Pepcid) /antacids (e.g., Rolaids) more than 3 times per week
  • Significant blood loss or blood donation in past 3 months
  • Active gastrointestinal bleed
  • Any surgery in the past 3 months
  • Hemochromatosis
  • Sickle cell disease
  • Hereditary polyposis
  • Rheumatoid arthritis
  • Type I or Type II diabetes
  • Smoker
  • Antibiotic use in the past 2 months
  • Excessive alcohol consumption [> 2 standard alcoholic drinks (12 ounces of beer, 5 ounces of wine, 1 shot of hard liquor) per day]
  • Aspirin use >81 mg/day OR >325 mg/every other day
  • Regularly taking probiotics, fiber supplements, Orlistat (over the counter brand name: Alli), or steroids (inhaled or oral)

Trial design

Primary purpose

Other

Allocation

Non-Randomized

Interventional model

Crossover Assignment

Masking

None (Open label)

17 participants in 3 patient groups

High heme iron diet
Other group
Treatment:
Other: High heme iron diet
Low iron diet
Other group
Treatment:
Other: Low iron diet
Plant-based high non-heme iron diet
Other group
Treatment:
Other: Plant-based high non-heme iron diet

Trial contacts and locations

1

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems